Best of ASCO® Montreal 2024: Head and Neck Cancer – Dr. Khashayar Esfahani

Best of ASCO® Montreal 2024: Head and Neck Cancer – Dr. Khashayar Esfahani

Best of ASCO® Montreal 2024
This content is for Canadian and Best of ASCO Montreal 2024 members only. Please update your profile if you believe this message is in error or contact us.
Icon Chair Speaker

Co-Chairs

Dr. Jamil Asselah
Dr. Kim Ma

Icon Chair Speaker

Speakers

Dr. Khashayar Esfahani

Studies/trials discussed:

  • Adjuvant PD-1 blockade with camrelizumab in high-risk locoregionally advanced nasopharyngeal carcinoma (DIPPER): A multicenter, open-label, phase 3, randomized controlled trial
  • Tislelizumab versus placebo combined with induction chemotherapy followed by concurrent chemoradiotherapy and adjuvant tislelizumab or placebo for locoregionally advanced nasopharyngeal carcinoma: Interim analysis of a multicenter, randomized, placebo-controlled, double-blind, phase 3 trial.
Tagged